医学
癌症
放射治疗
阶段(地层学)
放化疗
化疗
免疫疗法
疾病
肿瘤科
重症监护医学
内科学
外科
生物
古生物学
作者
Zheyu Song,Yuanyu Wu,Jiebing Yang,Dingquan Yang,Xuedong Fang
出处
期刊:Tumor Biology
[SAGE]
日期:2017-07-01
卷期号:39 (7): 101042831771462-101042831771462
被引量:792
标识
DOI:10.1177/1010428317714626
摘要
Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery is currently considered to be the only radical treatment. As surgical techniques improve and progress is made in traditional radiotherapy, chemotherapy, and the implementation of neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach >95%. However, the low rate of early diagnosis means that most patients have advanced-stage disease at diagnosis and so the best surgical window is missed. Therefore, the main treatment for advanced gastric cancer is the combination of neoadjuvant chemoradiotherapy, molecular-targeted therapy, and immunotherapy. In this article, we summarize several common methods used to treat advanced gastric cancer and discuss the progress made in the treatment of gastric cancer in detail. Only clinical practice and clinical research will allow us to prolong the survival time of patients and allow the patients to truly benefit by paying attention to the individual patient characteristics, drug choice, and developing a reasonable and comprehensive treatment plan.
科研通智能强力驱动
Strongly Powered by AbleSci AI